Comparison of generic, condition-specific, and mapped health state utility values for multiple myeloma cancer

Value in Health

Volumn 15, Issue 8, 2012, Pages 1059-1068

  Rowen, Donna ^a   Young, Tracey ^a,b   Brazier, John ^a   Gaugris, Sabine ^c  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c Janssen Cilag Ltd   (United Kingdom)

Author keywords

condition specific measures; mapping; preference based measures; QALYs; utility

Indexed keywords

AGED; ARTICLE; CANCER PATIENT; CONDITION SPECIFIC EORTC 8D; CONDITION SPECIFIC VALUE; CONTROLLED STUDY; COST UTILITY ANALYSIS; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISCRIMINANT VALIDITY; DISEASE SEVERITY; EQ 5D UTILITY VALUES; FEMALE; GENERIC EQ 5D; GENERIC UTILITY VALUE; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MAPPED UTILITY VALUE; MULTIPLE MYELOMA; PATIENT PREFERENCE; PHASE 3 CLINICAL TRIAL; PHYSICAL CAPACITY; PRIORITY JOURNAL; PSYCHOMETRY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; TREATMENT DURATION; TREATMENT RESPONSE;

EMOTIONS; GREAT BRITAIN; HEALTH CARE RATIONING; HEALTH STATUS; HUMANS; INTERPERSONAL RELATIONS; MULTIPLE MYELOMA; PAIN; PSYCHOMETRICS; QUALITY OF LIFE; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX;

EID: 84871197917     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2012.08.2201     Document Type: Article

References (31)

1. R. Brooks EuroQol: the current state of play Health Policy 37 1996 53 72 (Pubitemid 26191458)
2. D. Feeny, W. Furlong, and G.W. Torrance Multiattribute and single-attribute utility functions for the health utilities index mark 3 system Med Care 40 2002 113 128
3. J. Brazier, J. Roberts, and M. Deverill The estimation of a preference-based measure of health from the SF-36 J Health Econ 21 2002 271 292 (Pubitemid 34143147)
4. J.E. Brazier, and J. Roberts The estimation of a preference-based measure of health from the SF-12 Med Care 42 2004 851 859 (Pubitemid 39456916)
5. J.E. Brazier, J. Ratcliffe, J.A. Solomon, and A. Tsuchiya Measuring and Valuing Health for Economic Evaluation 2007 Oxford University Press Oxford
6. National Institute of Health and Clinical Excellence. Guide to the Methods of Technology Appraisal. London: National Institute of Health and Clinical Excellence, 2008.
7. M. Garau, K. Shah, and A. Towse Assessment and Appraisal of Oncology Medicines: Does NICE's Approach Include All Relevant Elements? What Can Be Learnt from International HTA Experiences? 2009 OHE Consulting London, UK
8. U.S. Department of Health and Human Services, Food and Drug Administration Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims 2009 Food and Drug Administration Rockville, Maryland
9. Y. Yang, J.E. Brazier, A. Tsuchiya, and TA. Young Estimating a preference-based index for a 5-dimensional health state classification for asthma derived from the asthma quality of life questionnaire Med Decis Making 31 2011 281 291
10. T.A. Young, Y. Yang, J.E. Brazier, and A. Tsuchiya The use of rasch analysis in reducing a large condition-specific instrument for preference valuation: the case of moving from AQLQ to AQL-5D Med Decis Making 31 2011 195 210
11. T. Young, Y. Yang, J.E. Brazier, A. Tsuchiya, and K. Coyne The first stage of developing preference-based measures: constructing a health-state classification using Rasch analysis Qual Life Res 18 2009 253 265
12. D. Rowen, J. Brazier, and T. Young Deriving a preference-based measure for cancer using the EORTC QLQ-C30 Value Health 14 2011 721 731
13. P. Dolan Modeling valuations for EuroQol health states Med Care 35 1997 1095 1108 (Pubitemid 127453463)
14. Longworth L., Rowen D. NICE DSU Technical Support Document 10: the use of mapping methods to estimate health state utility values. www.nicedsu.org.uk. [Accessed September 1, 2011].
15. L. McKenzie, and M. van der Pol Mapping the EORTC QLQ C-30 onto the EQ-5D instrument: the potential to estimate QALYs without generic preference data Value Health 12 2009 167 171
16. G.R. Barton, T.H. Sach, and C. Jenkinson Do estimates of cost-utility based on the EQ-5D differ from those based on the mapping of utility scores? Health Qual Life Outcomes 6 2008 51
17. L.H. Chuang, and P. Kind Converting the SF-12 into the EQ-5D: an empirical comparison of methodologies Pharmacoeconomics 27 2009 491 505
18. J.E. Brazier, D. Rowen, and I. Mavranezouli Developing and testing methods for deriving preference-based measures of health from condition-specific measures (and other patient-based measures of outcome) Health Technol Assess 16 2012 1 113
19. N.K. Aaronson, S. Ahmedzai, and B. Bregman The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology J Natl Cancer Inst 85 1993 365 376 (Pubitemid 23073154)
20. N. Kontodimopoulos, V.H. Aletras, D. Paliouras, and D. Niakas Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments Value Health 12 2009 1151 1157
21. R. Crott, and A. Briggs Mapping the QLQ-C30 quality of life cancer questionnaire to EQ-5D patient preferences Eur J Health Econ 11 2010 427 434
22. E.Q. Wu, P. Mulani, M.H. Farrell, and D. Sleep Mapping FACT-P and EORTC QLQ-C30 to patient health status measured by EQ-5D in metastatic hormone-refractory prostate cancer patients Value Health 10 2007 408 414 (Pubitemid 47481112)
23. A.S. Pickard, J.W. Shaw, and L. Hsiang-Wen A patient-based utility measure of health for clinical trials of cancer therapy based on the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Value Health 12 2009 977 988
24. M.M. Versteegh, and D. Rowen Brazier J, Stolk EA. Mapping onto EQ-5D for patients in poor health Health Qual Life Outcomes 8 2010 1 13
25. R.W. Jang, P.K. Isogai, and N. Mittmann Derivation of utility values from European Organization for Research and Treatment of Cancer Quality of Life-Core 30 Questionnaire Values in Lung Cancer J Thor Oncol 5 2010 1953 1957
26. E. Kim, S. Ko, and H. Kang Mapping the cancer-specific EORTC QLQ-C30 and EORTC QLQ-BR23 to the generic EQ-5D in metastatic breast cancer patients Qual Life Res 21 2012 1193 1203
27. M.M. Versteegh, A. Leunis, and J.J. Luime Mapping QLQ-C30, HAQ, and MSIS-29 on EQ-5D Med Decis Making 32 2012 554 568
28. M.R. Gold, J.E. Siegel, L.B. Russell, and M.C. Weinstein Cost-Effectiveness in Health and Medicine 1996 Oxford University Press Oxford
29. D. Karnofsky, and J. Burchenal The clinical evaluation of chemotherapeutic agents in cancer C. Macleod, Evaluation of Chemotherapeutic Agents 1949 Columbia University Press Columbia
30. J. Cohen Statistical Power Analysis for the Behavioural Sciences 1977 Academic Press New York
31. J.E. Brazier, Y. Yang, A. Tsuchiya, and D.L. Rowen A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures Eur J Health Econ 11 2010 215 225